The Lamivudine and Zidovudine Tablet, cataloged under National Stock Number 6505-01-462-9945, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Xlcare Pharmaceuticals Inc. Government technical data includes 3 specifications, cited from the U.S. Government catalog. The record lists 2 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 1 additional reference document (drawings, advisory and superseded references) is recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: BT.
| Parameter | Value |
|---|---|
| NSN | 6505-01-462-9945 |
| Primary Part Number | NDC72865-0144-60 |
| Item Name | Lamivudine and Zidovudine Tablet |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Xlcare Pharmaceuticals Inc |
| Status | ACTIVE |
| Administration | ORAL |
| Primary Container Content Quantity | 60.000 TABLETS |
| Primary Container Type | BOTTLE |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | BT |
| Part Number | Manufacturer |
|---|---|
| NDC49702-0202-18 | Viiv Healthcare Company Dba Viiv Healthcare Co (USA) |
| NDC72865-0144-60 PRIMARY | Xlcare Pharmaceuticals Inc (USA) |
| Reference | Meaning |
|---|---|
| 99-0123 | 5/1 Secondary reference U.S. Government activity |
NSN 6505-01-462-9945 is a Lamivudine and Zidovudine Tablet, manufactured by Xlcare Pharmaceuticals Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-462-9945 has 2 manufacturer part numbers on file: NDC49702-0202-18 (Viiv Healthcare Company Dba Viiv Healthcare Co), NDC72865-0144-60 (Xlcare Pharmaceuticals Inc).
Key specifications for NDC72865-0144-60: Administration: ORAL; Primary Container Content Quantity: 60.000 TABLETS; Primary Container Type: BOTTLE; Special Features: LAMIVUDINE AND ZIDOVUDINE TABLETS; 150MG LAMIVUDINE AND 300MG ZIDOVUDINE. 3 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.